{"entity":{"id":"imrecist","kind":"term","name":"imRECIST (immune-modified RECIST)","aka":["imRECIST","immune-modified RECIST"],"tldr":"imRECIST is a variant of the scan-measuring rules from atezolizumab trials that lets a response after apparent growth count, to capture benefit from immunotherapy that standard rules miss.","summary":"Hodi and colleagues (Journal of Clinical Oncology 2018) applied immune-modified RECIST to atezolizumab trial data in lung, bladder and kidney cancer and melanoma. It allows a best response after progressive disease and changes how new and non-target lesions define progression. Compared with RECIST 1.1, best overall response was 1 to 2 percentage points higher, disease control 8 to 13 points higher and median progression-free survival 0.5 to 1.5 months longer. Progression defined only by new lesions was not associated with longer survival.","asOf":"2026-11-04","links":[{"label":"Hodi et al., Immune-modified Response Evaluation Criteria In Solid Tumors (imRECIST) (J Clin Oncol 2018)","url":"https://doi.org/10.1200/jco.2017.75.1644"}],"tags":[],"related":["irecist","irrc","recist"],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Endpoints"},"route":"/terms/imrecist/","neighbours":{"term":[{"id":"irrc","kind":"term","name":"Immune-related response criteria (irRC)","route":"/terms/irrc/"},{"id":"irecist","kind":"term","name":"iRECIST (response criteria for immunotherapy trials)","route":"/terms/irecist/"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}]}}